Researchers at Weill Cornell Medicine have discovered that radiation therapy combined with two types of immunotherapy—one that boosts T cells, and another that boosts dendritic cells—can control tumors in preclinical models of triple negative breast cancer, a cancer type that’s typically resistant to immunotherapy alone. Immunotherapy activates the body’s own immune system to fight cancer but isn’t effective for difficult-to-treat “cold” tumors, like this.
The findings were published Aug. 24 in Nature Communications. Though radiation therapy has previously been combined with T-cell boosting immunotherapy, it rarely succeeds in eliminating cold tumors. The new, preclinical study found that activating another type of immune cell called a dendritic cell, in addition to the other two approaches, produced a synergistic effect that elicited tumor regression.
“I think this is quite exciting,” said principal investigator Dr. Sandra Demaria, professor of radiation oncology at Weill Cornell Medicine and pathologist at NewYork-Presbyterian/Weill Cornell Medical Center, who conducted the research under the auspices of the Department of Radiation Oncology. “There is so much room for improvement to provide more effective therapeutic options, especially for patients with cold tumors.”
Comments are closed.